Review



usp19 human shrna plasmid kit  (OriGene)


Bioz Verified Symbol OriGene is a verified supplier
Bioz Manufacturer Symbol OriGene manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    OriGene usp19 human shrna plasmid kit
    Univariate Cox Model for the Association Between Survival and Clinicopathological Features in GC
    Usp19 Human Shrna Plasmid Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tr308463/USP19+Human+shRNA+Plasmid+Kit/pmc07457554-149-15-28
    Average 90 stars, based on 1 article reviews
    usp19 human shrna plasmid kit - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer"

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer

    Journal: OncoTargets and therapy

    doi: 10.2147/OTT.S240543

    Univariate Cox Model for the Association Between Survival and Clinicopathological Features in GC
    Figure Legend Snippet: Univariate Cox Model for the Association Between Survival and Clinicopathological Features in GC

    Techniques Used: Expressing

    Relative expression of USP19 in GC cell lines and GES1. ( A ) Differential expression of USP19 mRNA in gastric cell lines by real-time PCR assay. ( B ) The differential expression of USP19 protein in gastric cell lines by WB analysis. ( C ) Differential expression and distribution of USP19 protein in gastric cell lines by confocal analysis, Scale bar=20 μm. ( D ) Relative expression of USP19 in paired 212 GC samples and ANTs by IHC staining and analysis by Chi-square test. ( E ) USP19 protein levels in GC tissues and ANTs were analyzed by IHC staining (200× magnification). High or low expression of USP19 protein in ANTs (a and b); high or low expression of USP19 protein in intestinal-type GC (c and d); high or low expression of USP19 protein in diffuse-type GC (e and f), Scale bar=200 μm.
    Figure Legend Snippet: Relative expression of USP19 in GC cell lines and GES1. ( A ) Differential expression of USP19 mRNA in gastric cell lines by real-time PCR assay. ( B ) The differential expression of USP19 protein in gastric cell lines by WB analysis. ( C ) Differential expression and distribution of USP19 protein in gastric cell lines by confocal analysis, Scale bar=20 μm. ( D ) Relative expression of USP19 in paired 212 GC samples and ANTs by IHC staining and analysis by Chi-square test. ( E ) USP19 protein levels in GC tissues and ANTs were analyzed by IHC staining (200× magnification). High or low expression of USP19 protein in ANTs (a and b); high or low expression of USP19 protein in intestinal-type GC (c and d); high or low expression of USP19 protein in diffuse-type GC (e and f), Scale bar=200 μm.

    Techniques Used: Expressing, Quantitative Proteomics, Real-time Polymerase Chain Reaction, Immunohistochemistry

    The Relationship Between USP19 Expression and Other Clinicopathological Parameters in GC
    Figure Legend Snippet: The Relationship Between USP19 Expression and Other Clinicopathological Parameters in GC

    Techniques Used: Expressing

    Kaplan–Meier survival curves of GC patients according to the clinical features and expression of USP19. ( A ) Patients with high-level USP19 expression showed poor survival. ( B ) TNM stage was a promising indicator of the prognosis of GC patients. ( C ) Patients with intestinal-type GC had better survival than those with diffuse-type GC. ( D ) Low-level USP19 expression predicted better survival in patients with TNM stage III. ( E ) Low-level USP19 expression predicted better survival in patients with diffuse-type GC. ( F ) Low-level USP19 expression predicted better survival in patients with intestinal-type GC.
    Figure Legend Snippet: Kaplan–Meier survival curves of GC patients according to the clinical features and expression of USP19. ( A ) Patients with high-level USP19 expression showed poor survival. ( B ) TNM stage was a promising indicator of the prognosis of GC patients. ( C ) Patients with intestinal-type GC had better survival than those with diffuse-type GC. ( D ) Low-level USP19 expression predicted better survival in patients with TNM stage III. ( E ) Low-level USP19 expression predicted better survival in patients with diffuse-type GC. ( F ) Low-level USP19 expression predicted better survival in patients with intestinal-type GC.

    Techniques Used: Expressing

    Multivariate Cox Model for the Association Between Survival and Clinicopathological Factors in GC
    Figure Legend Snippet: Multivariate Cox Model for the Association Between Survival and Clinicopathological Factors in GC

    Techniques Used: Expressing

    Functional roles of USP19 in cell models. ( A ) Knockdown of USP19 inhibited SGC7901 cell growth, as determined by MTT assay. Bars: SD; **P<0.01. ( B ) Knockdown of USP19 decreased the level of MMP2 and MMP9 and increased the level of the apoptotic-related protein, cleaved caspase-3, in SGC7901 cells. ( C ) Knockdown of USP19 inhibited colony formation in SGC7901 cells. The data are shown as Mean±SD (n=3). **P<0.01. ( D ) Ectopic expression of USP19 promoted GES1 cell growth, as shown by MTT assay. Bars: SD; **P<0.01. ( E ) Overexpression of USP19 increased the protein level of MMP2 and MMP9 and decreased the level of the apoptotic-related protein, cleaved caspase-3. ( F ) Ectopic expression of USP19 increased colony formation in GES1 cells. The data are shown as Mean±SD (n=3). **P<0.01. All WB experiments were repeated three times.
    Figure Legend Snippet: Functional roles of USP19 in cell models. ( A ) Knockdown of USP19 inhibited SGC7901 cell growth, as determined by MTT assay. Bars: SD; **P<0.01. ( B ) Knockdown of USP19 decreased the level of MMP2 and MMP9 and increased the level of the apoptotic-related protein, cleaved caspase-3, in SGC7901 cells. ( C ) Knockdown of USP19 inhibited colony formation in SGC7901 cells. The data are shown as Mean±SD (n=3). **P<0.01. ( D ) Ectopic expression of USP19 promoted GES1 cell growth, as shown by MTT assay. Bars: SD; **P<0.01. ( E ) Overexpression of USP19 increased the protein level of MMP2 and MMP9 and decreased the level of the apoptotic-related protein, cleaved caspase-3. ( F ) Ectopic expression of USP19 increased colony formation in GES1 cells. The data are shown as Mean±SD (n=3). **P<0.01. All WB experiments were repeated three times.

    Techniques Used: Functional Assay, Knockdown, MTT Assay, Expressing, Over Expression

    Effect of USP19 on cell invasion and migration and MMP2/MMP9 enzyme activity. ( A ) Knockdown of USP19 reduced SGC7901 cell invasion. Images were acquired at the indicated time (200× magnification). Data are shown as Mean±SD (n=5). **P<0.01. ( B ) Knockdown of USP19 reduced the migration of SGC7901 cells, as determined by wound healing assay at 0, 12, 24, and 36 h. Images were acquired at the indicated time (100× magnification). Data are shown as Mean±SD (n=3). **P<0.01. ( C ) SGC7901 cells were transfected with ShUSP19 or vector for 36 h and then subjected to gelatin zymography to analyze the activity of MMP2 and MMP9. ( D ) Ectopic expression of USP19 enhanced invasion of GES1 cells. Images were acquired at the indicated time (200× magnification). Data are shown as Mean±SD (n=5). **P<0.01. ( E ) Ectopic expression of USP19 increased the migration of GES1 cells, as determined by wound healing assay at 0, 12, 24, and 36 h. Images were acquired at the indicated time (100× magnification). Data are shown as Mean±SD (n=3). **P<0.01. ( F ) GES1 cells were transfected with USP19-overexpressing plasmid or control vector for 36 h and then subjected to gelatin zymography to analyze the activity of MMP2 and MMP9.
    Figure Legend Snippet: Effect of USP19 on cell invasion and migration and MMP2/MMP9 enzyme activity. ( A ) Knockdown of USP19 reduced SGC7901 cell invasion. Images were acquired at the indicated time (200× magnification). Data are shown as Mean±SD (n=5). **P<0.01. ( B ) Knockdown of USP19 reduced the migration of SGC7901 cells, as determined by wound healing assay at 0, 12, 24, and 36 h. Images were acquired at the indicated time (100× magnification). Data are shown as Mean±SD (n=3). **P<0.01. ( C ) SGC7901 cells were transfected with ShUSP19 or vector for 36 h and then subjected to gelatin zymography to analyze the activity of MMP2 and MMP9. ( D ) Ectopic expression of USP19 enhanced invasion of GES1 cells. Images were acquired at the indicated time (200× magnification). Data are shown as Mean±SD (n=5). **P<0.01. ( E ) Ectopic expression of USP19 increased the migration of GES1 cells, as determined by wound healing assay at 0, 12, 24, and 36 h. Images were acquired at the indicated time (100× magnification). Data are shown as Mean±SD (n=3). **P<0.01. ( F ) GES1 cells were transfected with USP19-overexpressing plasmid or control vector for 36 h and then subjected to gelatin zymography to analyze the activity of MMP2 and MMP9.

    Techniques Used: Migration, Activity Assay, Knockdown, Wound Healing Assay, Transfection, Plasmid Preparation, Zymography, Expressing, Control

    Knockdown of USP19 reduced gastric carcinogenesis in animal models. Knockdown of USP19 inhibited tumor growth. Five nude mice were injected subcutaneously with 1 × 10 7 cells/mouse for each of the indicated stable cell lines of SGC7901-ShUSP19 or SGC7901-Vector, respectively. Results were presented as tumor volume at the different time points ( C ) and isolated xenografts at day 24 ( A ) with no change in body weight for each group ( B ). **P<0.01. ( D ) Tumors were isolated, fixed, and subjected to IHC assay (400× magnification).
    Figure Legend Snippet: Knockdown of USP19 reduced gastric carcinogenesis in animal models. Knockdown of USP19 inhibited tumor growth. Five nude mice were injected subcutaneously with 1 × 10 7 cells/mouse for each of the indicated stable cell lines of SGC7901-ShUSP19 or SGC7901-Vector, respectively. Results were presented as tumor volume at the different time points ( C ) and isolated xenografts at day 24 ( A ) with no change in body weight for each group ( B ). **P<0.01. ( D ) Tumors were isolated, fixed, and subjected to IHC assay (400× magnification).

    Techniques Used: Knockdown, Injection, Stable Transfection, Plasmid Preparation, Isolation

    Prognostic roles of USP19 was determined in www.kmplot.com and correlation between mRNA levels of USP19 and MMP2/MMP9 in GC dataset from GEPIA Website ( http://gepia2.cancer-pku.cn ). Overall survival curves were plotted for all GC patients (n=876) with ( A ) different levels of USP19 expression; ( B ) Lauren’s classification; ( C and D ) HER2 status, ( E ) Different treatments, 5-FU based chemical therapy, ( F ) Surgery alone. From these data, low level of USP19 expression was correlated with better OS. The mRNA level of USP19 expression was positive association with MMP2/MMP9 expression. ( G) P<0.001 correlation between MMP9 and USP19; ( H ) P=0.062, correlation between MMP2 and USP19. Especially, the moderate correlation was performed between USP19 and MMP9 expression (Spearman’s R=0.24).
    Figure Legend Snippet: Prognostic roles of USP19 was determined in www.kmplot.com and correlation between mRNA levels of USP19 and MMP2/MMP9 in GC dataset from GEPIA Website ( http://gepia2.cancer-pku.cn ). Overall survival curves were plotted for all GC patients (n=876) with ( A ) different levels of USP19 expression; ( B ) Lauren’s classification; ( C and D ) HER2 status, ( E ) Different treatments, 5-FU based chemical therapy, ( F ) Surgery alone. From these data, low level of USP19 expression was correlated with better OS. The mRNA level of USP19 expression was positive association with MMP2/MMP9 expression. ( G) P<0.001 correlation between MMP9 and USP19; ( H ) P=0.062, correlation between MMP2 and USP19. Especially, the moderate correlation was performed between USP19 and MMP9 expression (Spearman’s R=0.24).

    Techniques Used: Expressing

    Related Articles

    Knockdown:

    Article Title: <p>USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer</p>
    Article Snippet: Transfection and Generation of Stable Cell Lines The specific ectopic expression USP19 plasmid (RC214190, USP19 [Myc-DDK-tagged]-Human USP19, NM_006677, transcript variant 4) with the vector control (pCMV6-Entry, CAT#: PS10,0001) were purchased from a commercial company (OriGene Ltd., Rockville, MD), and these plasmids were transfected into GES1 cells with 400μg/mL neomycin (Gibco) addition to form stable clones. .. The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene. com/catalog/rnai/shrna-plasmids/tr308463/usp19-humanshrna- plasmid-kit- locus- id-10,869). .. These shRNA constructs were designed against multiple splice variants at this gene locus, as well as the negative control-empty vector (pRS, CAT#: TR20003).

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer
    Article Snippet: The specific ectopic expression USP19 plasmid (RC214190, USP19 [Myc-DDK-tagged]-Human USP19, NM_006677, transcript variant 4) with the vector control (pCMV6-Entry, CAT#: PS10,0001) were purchased from a commercial company (OriGene Ltd., Rockville, MD), and these plasmids were transfected into GES1 cells with 400μg/mL neomycin (Gibco) addition to form stable clones. .. The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene.com/catalog/rnai/shrna-plasmids/tr308463/usp19-human-shrna- plasmid-kit- locus- id-10,869 ). .. These shRNA constructs were designed against multiple splice variants at this gene locus, as well as the negative control-empty vector (pRS, CAT#: TR20003).

    shRNA:

    Article Title: <p>USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer</p>
    Article Snippet: Transfection and Generation of Stable Cell Lines The specific ectopic expression USP19 plasmid (RC214190, USP19 [Myc-DDK-tagged]-Human USP19, NM_006677, transcript variant 4) with the vector control (pCMV6-Entry, CAT#: PS10,0001) were purchased from a commercial company (OriGene Ltd., Rockville, MD), and these plasmids were transfected into GES1 cells with 400μg/mL neomycin (Gibco) addition to form stable clones. .. The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene. com/catalog/rnai/shrna-plasmids/tr308463/usp19-humanshrna- plasmid-kit- locus- id-10,869). .. These shRNA constructs were designed against multiple splice variants at this gene locus, as well as the negative control-empty vector (pRS, CAT#: TR20003).

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer
    Article Snippet: The specific ectopic expression USP19 plasmid (RC214190, USP19 [Myc-DDK-tagged]-Human USP19, NM_006677, transcript variant 4) with the vector control (pCMV6-Entry, CAT#: PS10,0001) were purchased from a commercial company (OriGene Ltd., Rockville, MD), and these plasmids were transfected into GES1 cells with 400μg/mL neomycin (Gibco) addition to form stable clones. .. The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene.com/catalog/rnai/shrna-plasmids/tr308463/usp19-human-shrna- plasmid-kit- locus- id-10,869 ). .. These shRNA constructs were designed against multiple splice variants at this gene locus, as well as the negative control-empty vector (pRS, CAT#: TR20003).

    Plasmid Preparation:

    Article Title: <p>USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer</p>
    Article Snippet: Transfection and Generation of Stable Cell Lines The specific ectopic expression USP19 plasmid (RC214190, USP19 [Myc-DDK-tagged]-Human USP19, NM_006677, transcript variant 4) with the vector control (pCMV6-Entry, CAT#: PS10,0001) were purchased from a commercial company (OriGene Ltd., Rockville, MD), and these plasmids were transfected into GES1 cells with 400μg/mL neomycin (Gibco) addition to form stable clones. .. The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene. com/catalog/rnai/shrna-plasmids/tr308463/usp19-humanshrna- plasmid-kit- locus- id-10,869). .. These shRNA constructs were designed against multiple splice variants at this gene locus, as well as the negative control-empty vector (pRS, CAT#: TR20003).

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer
    Article Snippet: The specific ectopic expression USP19 plasmid (RC214190, USP19 [Myc-DDK-tagged]-Human USP19, NM_006677, transcript variant 4) with the vector control (pCMV6-Entry, CAT#: PS10,0001) were purchased from a commercial company (OriGene Ltd., Rockville, MD), and these plasmids were transfected into GES1 cells with 400μg/mL neomycin (Gibco) addition to form stable clones. .. The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene.com/catalog/rnai/shrna-plasmids/tr308463/usp19-human-shrna- plasmid-kit- locus- id-10,869 ). .. These shRNA constructs were designed against multiple splice variants at this gene locus, as well as the negative control-empty vector (pRS, CAT#: TR20003).



    Similar Products

    usp19 human shrna plasmid kit  (OriGene)
    90
    OriGene usp19 human shrna plasmid kit
    Univariate Cox Model for the Association Between Survival and Clinicopathological Features in GC
    Usp19 Human Shrna Plasmid Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tr308463/USP19+Human+shRNA+Plasmid+Kit/pmc07457554-149-15-28
    Average 90 stars, based on 1 article reviews
    usp19 human shrna plasmid kit - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    tr308463  (OriGene)
    90
    OriGene tr308463
    Univariate Cox Model for the Association Between Survival and Clinicopathological Features in GC
    Tr308463, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tr308463/USP19+Human+shRNA+Plasmid+Kit/pmc07457554-149-24-28
    Average 90 stars, based on 1 article reviews
    tr308463 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Univariate Cox Model for the Association Between Survival and Clinicopathological Features in GC

    Journal: OncoTargets and therapy

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer

    doi: 10.2147/OTT.S240543

    Figure Lengend Snippet: Univariate Cox Model for the Association Between Survival and Clinicopathological Features in GC

    Article Snippet: The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene.com/catalog/rnai/shrna-plasmids/tr308463/usp19-human-shrna- plasmid-kit- locus- id-10,869 ).

    Techniques: Expressing

    Relative expression of USP19 in GC cell lines and GES1. ( A ) Differential expression of USP19 mRNA in gastric cell lines by real-time PCR assay. ( B ) The differential expression of USP19 protein in gastric cell lines by WB analysis. ( C ) Differential expression and distribution of USP19 protein in gastric cell lines by confocal analysis, Scale bar=20 μm. ( D ) Relative expression of USP19 in paired 212 GC samples and ANTs by IHC staining and analysis by Chi-square test. ( E ) USP19 protein levels in GC tissues and ANTs were analyzed by IHC staining (200× magnification). High or low expression of USP19 protein in ANTs (a and b); high or low expression of USP19 protein in intestinal-type GC (c and d); high or low expression of USP19 protein in diffuse-type GC (e and f), Scale bar=200 μm.

    Journal: OncoTargets and therapy

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer

    doi: 10.2147/OTT.S240543

    Figure Lengend Snippet: Relative expression of USP19 in GC cell lines and GES1. ( A ) Differential expression of USP19 mRNA in gastric cell lines by real-time PCR assay. ( B ) The differential expression of USP19 protein in gastric cell lines by WB analysis. ( C ) Differential expression and distribution of USP19 protein in gastric cell lines by confocal analysis, Scale bar=20 μm. ( D ) Relative expression of USP19 in paired 212 GC samples and ANTs by IHC staining and analysis by Chi-square test. ( E ) USP19 protein levels in GC tissues and ANTs were analyzed by IHC staining (200× magnification). High or low expression of USP19 protein in ANTs (a and b); high or low expression of USP19 protein in intestinal-type GC (c and d); high or low expression of USP19 protein in diffuse-type GC (e and f), Scale bar=200 μm.

    Article Snippet: The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene.com/catalog/rnai/shrna-plasmids/tr308463/usp19-human-shrna- plasmid-kit- locus- id-10,869 ).

    Techniques: Expressing, Quantitative Proteomics, Real-time Polymerase Chain Reaction, Immunohistochemistry

    The Relationship Between USP19 Expression and Other Clinicopathological Parameters in GC

    Journal: OncoTargets and therapy

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer

    doi: 10.2147/OTT.S240543

    Figure Lengend Snippet: The Relationship Between USP19 Expression and Other Clinicopathological Parameters in GC

    Article Snippet: The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene.com/catalog/rnai/shrna-plasmids/tr308463/usp19-human-shrna- plasmid-kit- locus- id-10,869 ).

    Techniques: Expressing

    Kaplan–Meier survival curves of GC patients according to the clinical features and expression of USP19. ( A ) Patients with high-level USP19 expression showed poor survival. ( B ) TNM stage was a promising indicator of the prognosis of GC patients. ( C ) Patients with intestinal-type GC had better survival than those with diffuse-type GC. ( D ) Low-level USP19 expression predicted better survival in patients with TNM stage III. ( E ) Low-level USP19 expression predicted better survival in patients with diffuse-type GC. ( F ) Low-level USP19 expression predicted better survival in patients with intestinal-type GC.

    Journal: OncoTargets and therapy

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer

    doi: 10.2147/OTT.S240543

    Figure Lengend Snippet: Kaplan–Meier survival curves of GC patients according to the clinical features and expression of USP19. ( A ) Patients with high-level USP19 expression showed poor survival. ( B ) TNM stage was a promising indicator of the prognosis of GC patients. ( C ) Patients with intestinal-type GC had better survival than those with diffuse-type GC. ( D ) Low-level USP19 expression predicted better survival in patients with TNM stage III. ( E ) Low-level USP19 expression predicted better survival in patients with diffuse-type GC. ( F ) Low-level USP19 expression predicted better survival in patients with intestinal-type GC.

    Article Snippet: The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene.com/catalog/rnai/shrna-plasmids/tr308463/usp19-human-shrna- plasmid-kit- locus- id-10,869 ).

    Techniques: Expressing

    Multivariate Cox Model for the Association Between Survival and Clinicopathological Factors in GC

    Journal: OncoTargets and therapy

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer

    doi: 10.2147/OTT.S240543

    Figure Lengend Snippet: Multivariate Cox Model for the Association Between Survival and Clinicopathological Factors in GC

    Article Snippet: The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene.com/catalog/rnai/shrna-plasmids/tr308463/usp19-human-shrna- plasmid-kit- locus- id-10,869 ).

    Techniques: Expressing

    Functional roles of USP19 in cell models. ( A ) Knockdown of USP19 inhibited SGC7901 cell growth, as determined by MTT assay. Bars: SD; **P<0.01. ( B ) Knockdown of USP19 decreased the level of MMP2 and MMP9 and increased the level of the apoptotic-related protein, cleaved caspase-3, in SGC7901 cells. ( C ) Knockdown of USP19 inhibited colony formation in SGC7901 cells. The data are shown as Mean±SD (n=3). **P<0.01. ( D ) Ectopic expression of USP19 promoted GES1 cell growth, as shown by MTT assay. Bars: SD; **P<0.01. ( E ) Overexpression of USP19 increased the protein level of MMP2 and MMP9 and decreased the level of the apoptotic-related protein, cleaved caspase-3. ( F ) Ectopic expression of USP19 increased colony formation in GES1 cells. The data are shown as Mean±SD (n=3). **P<0.01. All WB experiments were repeated three times.

    Journal: OncoTargets and therapy

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer

    doi: 10.2147/OTT.S240543

    Figure Lengend Snippet: Functional roles of USP19 in cell models. ( A ) Knockdown of USP19 inhibited SGC7901 cell growth, as determined by MTT assay. Bars: SD; **P<0.01. ( B ) Knockdown of USP19 decreased the level of MMP2 and MMP9 and increased the level of the apoptotic-related protein, cleaved caspase-3, in SGC7901 cells. ( C ) Knockdown of USP19 inhibited colony formation in SGC7901 cells. The data are shown as Mean±SD (n=3). **P<0.01. ( D ) Ectopic expression of USP19 promoted GES1 cell growth, as shown by MTT assay. Bars: SD; **P<0.01. ( E ) Overexpression of USP19 increased the protein level of MMP2 and MMP9 and decreased the level of the apoptotic-related protein, cleaved caspase-3. ( F ) Ectopic expression of USP19 increased colony formation in GES1 cells. The data are shown as Mean±SD (n=3). **P<0.01. All WB experiments were repeated three times.

    Article Snippet: The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene.com/catalog/rnai/shrna-plasmids/tr308463/usp19-human-shrna- plasmid-kit- locus- id-10,869 ).

    Techniques: Functional Assay, Knockdown, MTT Assay, Expressing, Over Expression

    Effect of USP19 on cell invasion and migration and MMP2/MMP9 enzyme activity. ( A ) Knockdown of USP19 reduced SGC7901 cell invasion. Images were acquired at the indicated time (200× magnification). Data are shown as Mean±SD (n=5). **P<0.01. ( B ) Knockdown of USP19 reduced the migration of SGC7901 cells, as determined by wound healing assay at 0, 12, 24, and 36 h. Images were acquired at the indicated time (100× magnification). Data are shown as Mean±SD (n=3). **P<0.01. ( C ) SGC7901 cells were transfected with ShUSP19 or vector for 36 h and then subjected to gelatin zymography to analyze the activity of MMP2 and MMP9. ( D ) Ectopic expression of USP19 enhanced invasion of GES1 cells. Images were acquired at the indicated time (200× magnification). Data are shown as Mean±SD (n=5). **P<0.01. ( E ) Ectopic expression of USP19 increased the migration of GES1 cells, as determined by wound healing assay at 0, 12, 24, and 36 h. Images were acquired at the indicated time (100× magnification). Data are shown as Mean±SD (n=3). **P<0.01. ( F ) GES1 cells were transfected with USP19-overexpressing plasmid or control vector for 36 h and then subjected to gelatin zymography to analyze the activity of MMP2 and MMP9.

    Journal: OncoTargets and therapy

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer

    doi: 10.2147/OTT.S240543

    Figure Lengend Snippet: Effect of USP19 on cell invasion and migration and MMP2/MMP9 enzyme activity. ( A ) Knockdown of USP19 reduced SGC7901 cell invasion. Images were acquired at the indicated time (200× magnification). Data are shown as Mean±SD (n=5). **P<0.01. ( B ) Knockdown of USP19 reduced the migration of SGC7901 cells, as determined by wound healing assay at 0, 12, 24, and 36 h. Images were acquired at the indicated time (100× magnification). Data are shown as Mean±SD (n=3). **P<0.01. ( C ) SGC7901 cells were transfected with ShUSP19 or vector for 36 h and then subjected to gelatin zymography to analyze the activity of MMP2 and MMP9. ( D ) Ectopic expression of USP19 enhanced invasion of GES1 cells. Images were acquired at the indicated time (200× magnification). Data are shown as Mean±SD (n=5). **P<0.01. ( E ) Ectopic expression of USP19 increased the migration of GES1 cells, as determined by wound healing assay at 0, 12, 24, and 36 h. Images were acquired at the indicated time (100× magnification). Data are shown as Mean±SD (n=3). **P<0.01. ( F ) GES1 cells were transfected with USP19-overexpressing plasmid or control vector for 36 h and then subjected to gelatin zymography to analyze the activity of MMP2 and MMP9.

    Article Snippet: The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene.com/catalog/rnai/shrna-plasmids/tr308463/usp19-human-shrna- plasmid-kit- locus- id-10,869 ).

    Techniques: Migration, Activity Assay, Knockdown, Wound Healing Assay, Transfection, Plasmid Preparation, Zymography, Expressing, Control

    Knockdown of USP19 reduced gastric carcinogenesis in animal models. Knockdown of USP19 inhibited tumor growth. Five nude mice were injected subcutaneously with 1 × 10 7 cells/mouse for each of the indicated stable cell lines of SGC7901-ShUSP19 or SGC7901-Vector, respectively. Results were presented as tumor volume at the different time points ( C ) and isolated xenografts at day 24 ( A ) with no change in body weight for each group ( B ). **P<0.01. ( D ) Tumors were isolated, fixed, and subjected to IHC assay (400× magnification).

    Journal: OncoTargets and therapy

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer

    doi: 10.2147/OTT.S240543

    Figure Lengend Snippet: Knockdown of USP19 reduced gastric carcinogenesis in animal models. Knockdown of USP19 inhibited tumor growth. Five nude mice were injected subcutaneously with 1 × 10 7 cells/mouse for each of the indicated stable cell lines of SGC7901-ShUSP19 or SGC7901-Vector, respectively. Results were presented as tumor volume at the different time points ( C ) and isolated xenografts at day 24 ( A ) with no change in body weight for each group ( B ). **P<0.01. ( D ) Tumors were isolated, fixed, and subjected to IHC assay (400× magnification).

    Article Snippet: The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene.com/catalog/rnai/shrna-plasmids/tr308463/usp19-human-shrna- plasmid-kit- locus- id-10,869 ).

    Techniques: Knockdown, Injection, Stable Transfection, Plasmid Preparation, Isolation

    Prognostic roles of USP19 was determined in www.kmplot.com and correlation between mRNA levels of USP19 and MMP2/MMP9 in GC dataset from GEPIA Website ( http://gepia2.cancer-pku.cn ). Overall survival curves were plotted for all GC patients (n=876) with ( A ) different levels of USP19 expression; ( B ) Lauren’s classification; ( C and D ) HER2 status, ( E ) Different treatments, 5-FU based chemical therapy, ( F ) Surgery alone. From these data, low level of USP19 expression was correlated with better OS. The mRNA level of USP19 expression was positive association with MMP2/MMP9 expression. ( G) P<0.001 correlation between MMP9 and USP19; ( H ) P=0.062, correlation between MMP2 and USP19. Especially, the moderate correlation was performed between USP19 and MMP9 expression (Spearman’s R=0.24).

    Journal: OncoTargets and therapy

    Article Title: USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer

    doi: 10.2147/OTT.S240543

    Figure Lengend Snippet: Prognostic roles of USP19 was determined in www.kmplot.com and correlation between mRNA levels of USP19 and MMP2/MMP9 in GC dataset from GEPIA Website ( http://gepia2.cancer-pku.cn ). Overall survival curves were plotted for all GC patients (n=876) with ( A ) different levels of USP19 expression; ( B ) Lauren’s classification; ( C and D ) HER2 status, ( E ) Different treatments, 5-FU based chemical therapy, ( F ) Surgery alone. From these data, low level of USP19 expression was correlated with better OS. The mRNA level of USP19 expression was positive association with MMP2/MMP9 expression. ( G) P<0.001 correlation between MMP9 and USP19; ( H ) P=0.062, correlation between MMP2 and USP19. Especially, the moderate correlation was performed between USP19 and MMP9 expression (Spearman’s R=0.24).

    Article Snippet: The specific kit for knockdown of USP19 was ordered from the commercial company (OriGene, Ltd.; USP19 Human shRNA Plasmid Kit [Locus ID 10,869], CAT#: TR308463, ordered from https://www. origene.com/catalog/rnai/shrna-plasmids/tr308463/usp19-human-shrna- plasmid-kit- locus- id-10,869 ).

    Techniques: Expressing